Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma

Abstract Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib and transhepatic arteri...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lei Dai, Xingchen Cai, Joseph Mugaanyi, Yelei Liu, Shuqi Mao, Changjiang Lu, Caide Lu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/9b1520d14dc04bf4ade1cd443cc489c1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!